Interní Med. 2006; 8(5): 214-218

Current opinion on patients with increased cardiovascular risk

prof. MUDr. Jiří Vítovec CSc, prof. MUDr. Jindřich ©pinar CSc., FESC
I. interní kardioangiologická klinika FN u sv. Anny v Brně

Authors present a review of algorhytms in primary prevention of high-risk patients and secondary prevention of cardiovascular diseases. Besides nonpharmacological methods the pharmacotherapy is emphasized: renin-angiotensin system inhibitors – ACE-inhibitors and sartans, beta-blockers, antiplatelet treatment, acetylosalicylic acid with clopidogrel and statins.

Keywords: Key words: ACE-inhibitors, angiotensin receptor blockers, beta-blockers, acetylosalicylic acid, clopidogrel, inhibitors 3HMG CoA reductase.

Published: June 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, ©pinar J. Current opinion on patients with increased cardiovascular risk. Interní Med. 2006;8(5):214-218.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arnold JMO, Yusuf S, Young J, et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107: 1284-1290. Go to original source... Go to PubMed...
    2. Backer G, Ambrosioni E, Borch-Jonsen K, et al: European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-1610. Go to original source... Go to PubMed...
    3. Bělohlávek J, Aschermann M. Kyselina acetylsalicylová a ACE inhibitory u kardiaků - fenomén pejska a kočičky? Vnitřní Lék 2002; 48: 695-697.
    4. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-1840. Go to original source... Go to PubMed...
    5. Bhat DL, Keith AA, Fox MB et al. For the CHARISMA study investigators: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: published at www.nejm.org on Mar 12, 2006. Go to PubMed...
    6. Bosch J. Extended follow-up of the ramipril component of the Heart Outcomes Prevention Evaluation (HOPE-TOO). Presented at the ESC Congress 2003; Vienna, Austria. Clinical Trial Update III Hypertension/Prevention, Presentation No 3711.
    7. Cífková R, a spol. Prevence kardiovaskulárních onemocnění v dospělém věku Společné doporučení českých odborných společností Cor Vasa 2005; 47 (9-Suppl): 3-14.
    8. Cífková R. Studie HOPE a MICROHOPE. Kapit.kardiol 2001; 3: 30-31.
    9. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 2002; 324, 7329: 71-86. Go to PubMed...
    10. Čeąka R. a spol. Cholesterol a ateroskleróza, léčba dyslipidemií. Praha Triton 2005: 343.
    11. Diener HC, Bogousslavsky J, Brass LM et al on behalf of the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high risk patiens (MATCH): randomised, double blind, placebo controlled trial. Lancet 2004; 364: 331-337. Go to original source... Go to PubMed...
    12. Figulla HR, Krzeminska-Pakula M, Wrabec K, et al. Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III Result of a randomized multicenter trial (BETACAR Trial). Int J Cardiol. 2006; 108: in press. Go to original source... Go to PubMed...
    13. Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the National Cholesterol Education Program, Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-239. Go to original source... Go to PubMed...
    14. Hradec J. Clopidogrel - antiagregans nové generace a studie CAPRIE. Remedia 1997; 7: 383-385.
    15. Krupička J. Nové indikace v pouľití inhibitorů ACE. Remedia 2002; 12: 117-121.
    16. Linhart A. ACE-inhibitory a blokátory AT1 - receptorů v aktuální kardiovaskulární farmakoterapii - Kardiol Rev 2003: 4: 25-30.
    17. Patrono C, Bachmann F, Baigent C, et al. Expert Concensus Document on the Use of Antiplatelet Agents. Europ Heart J 2004; 25: 166-181. Go to original source... Go to PubMed...
    18. Penka M. Kyselina acetylsalicylová - je nám vąe jasné? Spíąe není. Vnitřní Lék 2002; 48: 698-700.
    19. Pitt B. ACE inhibitors for patients with vascular disease without left ventricular dysfunction - may they rest in peace? N Engl J Med. 2004; 351: 2115-2117. Go to original source... Go to PubMed...
    20. Ringleb PA, Bhatt DL, Hirsch AT, et al. Benefit of clopidogrel over aspirin is amplified in patiens with a history of ischemic events. Stroke 2004; 35: 528-532. Go to original source... Go to PubMed...
    21. Sabatine MS, Cannon ChP, Gibson CM, et al. Addition of Clopidogrel to aspirin and Fibrinolytic Therapy for Myocardial Infarction witjh ST-Segment Elevation (CLARITY). N Eng J Med 2005; 352: 1179-1189. Go to original source... Go to PubMed...
    22. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. Eur Heart J 2005; 26: 804-808. Go to original source... Go to PubMed...
    23. ©paček R. Inhibitory ACE v léčbě a sekundární prevenci infarktu myokardu. Remedia 2002; 12: 102-107.
    24. ©pinar J, Vítovec J, Kubecová L, Pařenica J. Klinické studie v kardiologii. Grada 2001: 485 s.
    25. ©pinar J, Vítovec J. ASA - je nám vąe jasné? Vnitřní Lék 2002; 48: 781-790.
    26. ©pinar J, Vítovec J. EUROPA přepisuje guidelines. Kardiol rev 2003; 5: 191-193.
    27. ©tejfa M. Clopidogrel v léčbě akutního koronárního syndromu. Kardiol Rev 2001; 3: 184.
    28. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: (the EUROPA study). Lancet 2003; 362: 782-788.
    29. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004; 351: 2058-2068. Go to original source... Go to PubMed...
    30. Vítovec J, ©pinar J. Farmakoterapie kardiovaskulárních onemocnění. Grada 2004; 248 s.
    31. Widimský P. Studie EUROPA: Úspěch perindoprilu a české kardiologie. Cor Vasa 2004; 46: 7-8.
    32. Widimský P, Janouąek S, Vojáček J. Doporučení pro diagnostiku a léčbu akutního infarktu myokardu (Q-typ/s elevacemi ST/raménkovým blokem). Cor Vasa 2002; 44: K123-143.
    33. Yusuf S, Sleight P, Pogue J, et al. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145-153. Go to original source... Go to PubMed...
    34. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2003; 89 (Suppl 1): 18-25. Go to original source... Go to PubMed...
    35. Zanchetti A for the guidelines committee: 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hyperten 2003; 21: 1011-1023. Go to original source... Go to PubMed...
    36. Widimský J. Studie MRC/BHF- Heart Protection Study Cor Vasa 2002; 44: 161-165.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.